Quantcast

Latest TroVax Stories

2010-05-28 17:51:22

Small but decisive study highlights differences in clear- and non-clear cell subtypes.

2010-05-13 09:11:00

COLUMBIA, Md., May 13 /PRNewswire-FirstCall/ -- Celsion Corporation (Nasdaq: CLSN) announced today that after reviewing data from 294 patients including data from 12 Japanese patients enrolled in the pivotal Phase III ThermoDox® clinical study (HEAT Study) for primary liver cancer, the Data Monitoring Committee (DMC) has recommended that Celsion continue to enroll patients in the trial.

2010-04-15 11:41:00

COLUMBIA, Md., April 15 /PRNewswire-FirstCall/ -- Celsion Corporation (Nasdaq: CLSN) today announced that Dr. Ronnie T.P.

2010-04-12 06:30:00

COLUMBIA, Md., April 12 /PRNewswire/ -- Celsion Corporation (Nasdaq: CLSN) today announced that Dr. Ronnie T.P.

2010-04-09 09:49:17

Leukemia related protein 16 (LRP16) gene is an important estrogen-responsive gene.

2010-03-09 06:30:00

CALGARY, March 9 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.

2010-03-03 17:07:00

BRIDGEWATER, N.J., March 3 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today results from a Phase 3 trial which demonstrated cabazitaxel, an investigational compound, plus prednisone/prednisolone significantly improved overall survival and progression-free survival in patients with metastatic (advanced) hormone-refractory prostate cancer whose disease progressed following treatment with docetaxel-based chemotherapy.

2010-02-25 12:02:00

BELLEVUE, Wash., Feb. 25 /PRNewswire/ -- Light Sciences Oncology, Inc. (LSO) today announced the achievement of a major milestone in its late-stage clinical development of Aptocine(TM) (talaporfin sodium) for treatment of solid tumors.

2010-02-11 12:55:00

AMES, Iowa, Feb. 11 /PRNewswire/ -- NewLink Genetics Corporation announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process for a pivotal Phase 3 trial of its HyperAcute immunotherapy in pancreatic cancer.

2010-02-04 15:24:37

The drug pazopanib (Votrient) slowed the progression of advanced renal cell carcinoma (RCC), a form of kidney cancer, in patients by 54% percent, according to a new study published in the Journal of Clinical Oncology.